Enhancing Tetrahydrocannabinol’s Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011

Background/Objectives: Current inflammatory bowel disease (IBD) treatments focus on symptomatic relief, highlighting the need for innovative approaches. Dysregulation of the cannabinoid 1 (CB1) receptor, part of the endocannabinoid system, is linked to colitis. While tetrahydrocannabinol (THC) allev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceuticals (Basel, Switzerland) Jg. 18; H. 2; S. 148
Hauptverfasser:	Thapa, Dinesh, Patil, Mohan, Warne, Leon N, Carlessi, Rodrigo, Falasca, Marco
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 01.02.2025 MDPI
Schlagworte:	Ammonia Cannabidiol cannabinoid 1 receptor (CB1R) CB1R allosteric modulator Colon Diarrhea Drug therapy DSS-induced ulcerative colitis Homeostasis Inflammation Inflammatory bowel disease Inflammatory bowel diseases Nervous system agents Pain Testing Tetrahydrocannabinol tetrahydrocannabinol (THC) THC ZCZ011 Australia CB1R allosteric modulator ZCZ011 glucagon-like peptide 1 (GLP-1) cannabinoid 1 receptor (CB1R) ammonia cannabidiol (CBD) DSS-induced ulcerative colitis inflammatory bowel disease tetrahydrocannabinol (THC)
ISSN:	1424-8247, 1424-8247
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!